CN107937528A - 胶质瘤预后标志物hsa_circ_0125365及应用 - Google Patents
胶质瘤预后标志物hsa_circ_0125365及应用 Download PDFInfo
- Publication number
- CN107937528A CN107937528A CN201711453665.8A CN201711453665A CN107937528A CN 107937528 A CN107937528 A CN 107937528A CN 201711453665 A CN201711453665 A CN 201711453665A CN 107937528 A CN107937528 A CN 107937528A
- Authority
- CN
- China
- Prior art keywords
- circ
- glioma
- hsa
- samples
- circrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 61
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 50
- 239000003550 marker Substances 0.000 title claims abstract description 9
- 241000282414 Homo sapiens Species 0.000 claims abstract description 24
- 238000004393 prognosis Methods 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims abstract description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 238000010839 reverse transcription Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 5
- 230000004083 survival effect Effects 0.000 abstract description 11
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 229940048102 triphosphoric acid Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- -1 chloromethanes Alkane Chemical class 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于生物技术领域，公开了一种胶质瘤预后标志物hsa_circ_0125365及应用。即检测胶质瘤组织来源的circRNA hsa_circ_0125365表达量的试剂用于制备胶质瘤患者的预后制剂。通过研究证实胶质瘤中circRNA hsa_circ_0125365表达量较高的患者，拥有更高的术后生存率。通过检测胶质瘤患者胶质瘤组织中circRNA hsa_circ_0125365的表达水平，从而对胶质瘤患者做出预后判断。
Description
技术领域
本发明属于生物技术领域，涉及一种用于胶质瘤预后的circRNA标志物、以及检测该标志物的试剂用于制备胶质瘤预后制剂的应用、还有试剂盒。
背景技术
脑胶质瘤是成年人最为频发的脑肿瘤疾病，占颅内肿瘤的40.49％。从确诊开始，脑胶质瘤患者平均生存寿命不超过五年。为了诊治胶质瘤这种与遗传物质相关性极高的恶性疾病，必须在分子生物学水平，从遗传信息表达的方面来探索其发病机理。目前而言胶质瘤的诊断和治疗方法虽处于不断改进阶段，但是胶质瘤患者生存率并没有明显提高。胶质瘤诊断仍然处于以临床、病理学和影像学信息为基础的经验性阶段，而且一经诊断，绝大多数均为中晚期，手术后的生存率不容乐观。因此，寻找胶质瘤预后标志物对患者进行预后分析，以及提高胶质瘤患者的术后生活质量，并相应地选择合理的后续治疗方案，提高生存率，是神经科学领域亟待解决的研究任务。
circRNA是一类广泛且多样地存在于哺乳动物细胞中、具有调控基因表达作用的内源性非编码RNA分子，具有共价闭合的环形结构，广泛存在于各种细胞中，也是继microRNA(miRNA)后RNA家族的最新研究热点。近年来，随着深度测序技术的广泛应用和生物物理和信息学技术的快速发展，人们发现人类许多外显子的转录本可被非线性地反向剪接或通过基因重排而形成circRNA，且它们在所有剪接转录本中占了相当大的比例，并具有丰富性、稳定性、高保守性和时空特异性等特征，有作为诸多疾病分子标志物的潜力。
发明内容
本发明的第一个目的是：提供一种用于胶质瘤患者预后的胶质瘤组织来源的circRNA标志物hsa_circ_0125365，其序列如SEQ NO:1所示。
本发明的第二个目的是，提供检测所述的circRNA标志物在胶质瘤组织中表达量的试剂在制备胶质瘤预后制剂中的应用。
本发明的第三个目的是，提供一种胶质瘤预后试剂盒，能够测定胶质瘤组织中的hsa_circ_0125365的含量。
所述的胶质瘤预后试剂盒，含有检测hsa_circ_0125365含量的PCR引物。优选引物的序列如SEQ NO:2和3所示。
所述的胶质瘤预后试剂盒，除hsa_circ_0125365的引物外，还含有从胶质瘤组织中提取RNA并进行逆转录及荧光定量PCR的所有试剂。包括：
(1)从胶质瘤组织中抽提总RNA所用试剂，包括RNA稳定溶液、Trizol试剂、三氯甲烷、异丙醇、无酶水；
(2)以总RNA为模板将hsa_circ_0125365逆转录为cDNA所用试剂，包括逆转录缓冲液、三磷酸碱基脱氧核苷酸、RNA酶抑制剂、MMLV逆转录酶以及hsa_circ_0125365所用随机引物；
(3)将cDNA实时定量PCR所用试剂，包括circRNA hsa_circ_0125365实时荧光定量PCR特异性引物、GAPDH内参特异性PCR引物、实时荧光定量SYBR染料、无酶水。
本发明研究证实胶质瘤组织来源的circRNA hsa_circ_0125365可用于胶质瘤患者预后分析，胶质瘤组织来源的circRNA hsa_circ_0125365表达量与患者术后生存率具有相关性。因此，可用于胶质瘤患者的预后分析。
申请人通过荧光定量PCR对26例胶质瘤组织与12例正常脑组织进行分析发现，hsa_circ_0125365在两者中的表达差异明显(P＜0.0001)，之后对其中15例胶质瘤患者进行生存曲线分析，发现胶质瘤组织来源的circRNA hsa_circ_0125365与患者的生存率相关，含量越高，生存率越高。此法为胶质瘤的预后分析提供了强有力的技术支持，有助于提高胶质瘤患者的术后生活质量，制订术后治疗方案，提高生存率，具有深远的临床意义和推广性。
附图说明
图1为实时荧光定量PCR分析hsa_circ_0125365在胶质瘤组织与正常脑组织中表达差异；
图2为ROC曲线分析脑组织来源的hsa_circ_0125365对胶质瘤与正常脑组织差异的特异性、灵敏性；hsa_circ_0125365作为生物标记物对胶质瘤具有较高诊断价值(AUC＝0.939，P＝0.040，敏感度和特异度分别为90.0％和78.3％)。
图3为生存曲线分析胶质瘤组织来源的circRNA hsa_circ_0125365表达量与患者生存率的相关性。
具体实施方式
以下结合实施例旨在进一步说明本发明，而非限制本发明。
实施例1：制备检测circRNA hsa_circ_0125365表达量的试剂用于制备胶质瘤患者预后的试剂盒(50次反应)
1.RNA稳定溶液50ml
2.异丙醇100ml
3.三氯甲烷100ml
4.Trizol(来自Molecular Research Center公司)50ml
5.无酶水10ml
6.1μM随机逆转录引物(Thermo公司)50μl
7.5×逆转录缓冲液(Thermo公司)200ml
8.10mM三磷酸碱基脱氧核苷酸(Thermo公司)100μl
9.40U/μl RNA酶抑制剂(Thermo公司)500μl
10.200U/μl MMLV逆转录酶(Thermo公司)50μl
11.Premix Ex Taq(Thermo公司)50μl
12.10μM circRNA hsa_circ_0125365实时荧光定量PCR特异性引物30μl
circRNA hsa_circ_0125365正向引物：5'-CCAAGCAGCTCACTACGATA-3'，
circRNA hsa_circ_0125365反向引物：5'-CAAGCAGGTAGGAGATTCCA-3'；
13.10μM GAPDH特异性引物30μl
正向引物为5′-ATCAAGATCATTGCTCCTCCTGAG-3′，
反向引物为5′-CTGCTTGCTGATCCACATCTG-3′。
实施例2：circRNA hsa_circ_0125365在胶质瘤组织的表达量与预后的关系
1、胶质瘤组织的保存：收集待测胶质瘤组织存放于盛有RNA稳定溶液的冻存管中，放至-80℃冰箱备用。
2、组织中RNA的抽提：取适量标本于经180℃烘烤6-8h后的研钵中加入液氮研磨标本，研磨至粉末状后于研钵中加入1ml Trizol研钵标本，研磨成液体状后移至tube管，加氯仿200μl于Tube中，用手震荡15-30s，冰上放置15min，4℃12000rpm离心15min；小心取上层水相入新tube中，加入预冷的异丙醇0.5ml混匀，冰上静置20min，4℃12000rPm离心10min；弃上清，加入75％DEPC水稀释的乙醇1-2ml混匀，4℃，7500rPm离心5min，尽量弃上清，室温干燥5-10min，加入DEPC水10-20μl溶解RNA，-80℃保存。
3、circRNA hsa_circ_0125365逆转录：使用Thermo公司的逆转录试剂盒。20μl逆转录反应的体系如下：
逆转录第一步条件：65℃5分钟
| 成分 | 剂量/管 |
| 5×逆转录缓冲液 | 4μl |
| 三磷酸碱基脱氧核苷酸(10mM) | 2μl |
| RNA 酶抑制剂(40U/μl) | 1μl |
| MMLV逆转录酶(200U/μl) | 1μl |
| 第一步逆转录的产物 | 12μl |
| 总体积 | 20μl |
逆转录第二步程序：25℃5分钟，42℃60分钟，70℃5分钟。
4、汉恒生物科技(上海)有限公司合成的circRNA hsa_circ_0125365特异性引物进行实时定量PCR：先将逆转录产物稀释10倍，混匀。20μl反应体系如下：
PCR的特异性引物：
正向引物：5'-CCAAGCAGCTCACTACGATA-3'，
反向引物：5'-CAAGCAGGTAGGAGATTCCA-3'。
GAPDH内参特异性PCR引物：
正向引物为5′-ATCATCAGCAATGCCTCCT-3′，
反向引物为5′-CATCACGCCACAGTTTCC-3′。
实时荧光定量PCR反应程序：95℃3分钟,40个循环，95℃10秒，60℃30秒。
5、2-ΔΔCT的标定：用2-ΔΔCT表示对于对照组变化的倍数，其中△CT＝CT样本–CT内参，△△CT＝△CT病例–△CT对照。本实验数据采用相对定量的分析方法，GAPDH作为内参基因，胶质瘤患者△CT的平均值为对照。数据利用软件GraPhPad Prism和SPSS进行分析。申请人通过荧光定量PCR对26例胶质瘤组织与12例正常脑组织进行分析发现，hsa_circ_0125365在两者中的表达差异明显(P＜0.0001)，见图1。
6、图2的ROC曲线分析脑组织来源的hsa_circ_0125365对胶质瘤与正常脑组织差异的特异性、灵敏性；hsa_circ_0125365作为生物标记物对胶质瘤具有较高诊断价值(AUC＝0.939，P＝0.040，敏感度和特异度分别为90.0％和78.3％)。
7、对16位患者预后生存曲线分析发现，与胶质瘤组织中circRNA hsa_circ_0125365低表达(低于平均值)的患者相比，胶质瘤组织中circRNA hsa_circ_0125365高表达(高于平均值)的患者存活率更高，差异有显著性(P＝0.119)，见图3。
以上研究表明，hsa_circ_0125365可作为胶质瘤患者预后的特异性分子标志物。
序列表
<110> 中南大学湘雅医院
<120> 胶质瘤预后标志物hsa_circ_0125365及应用
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 568
<212> RNA
<213> 智人(Homo sapiens)
<400> 1
uggaagcauc aguucacagc aguaaugcac acuguacaga uaagacaauu gaagcugcug 60
aagcccugcu ucauauggaa ucuccuaccu gcuugaggga uucaagaagu ccuguggaag 120
uguuuguucc uccuugugua ucaacuccag aauucaucca ugcugcuaug aggccagaug 180
ucauuacaga aacuguagug gaggugucaa cugaagaguc ugaacccaug gauaccucuc 240
cuauuccaac aucaccagau agccaugaac caaugaaaaa gaaaaaaguu ggccguaaac 300
caaagaccca gcaaucacca auuuccaaug ggucuccuga guuagguaua aagaagaaac 360
caagagaagg aaaaggaaac acaaccuauu ugugggaguu ucuuuuagau cuacuucaag 420
auaaaaauac uugucccagg uauauuaaau ggacucagag agaaaaaggc auauucaagc 480
ugguggauuc aaaggcuguc ucuaagcuuu ggggaaagca uaagaacaaa ccagacauga 540
acuaugaaac caugggacga gcuuugag 568
<210> 2
<211> 20
<212> DNA
<213> 未知(Unknown)
<400> 2
ccaagcagct cactacgata 20
<210> 3
<211> 20
<212> DNA
<213> 未知(Unknown)
<400> 3
caagcaggta ggagattcca 20
<210> 4
<211> 19
<212> DNA
<213> 未知(Unknown)
<400> 4
atcatcagca atgcctcct 19
<210> 5
<211> 18
<212> DNA
<213> 未知(Unknown)
<400> 5
catcacgcca cagtttcc 18
Claims (6)
1.一种胶质瘤预后标志物hsa_circ_0125365，其序列如SEQ NO:1所示。
2.检测权利要求1所述的标志物在胶质瘤组织中表达量的试剂在制备胶质瘤预后制剂中的应用。
3.一种胶质瘤预后试剂盒，其特征在于，能够测定胶质瘤组织中的hsa_circ_0125365的含量。
4.根据权利要求3所述的胶质瘤预后试剂盒，其特征在于，含有检测hsa_circ_0125365含量的PCR引物。
5.根据权利要求4所述的胶质瘤预后试剂盒，其特征在于，引物的序列如SEQ NO:2和3所示。
6.根据权利要求3或4或5所述的胶质瘤预后试剂盒，其特征在于，除hsa_circ_0125365的引物外，还含有从胶质瘤组织中提取RNA并进行逆转录及荧光定量PCR的所有试剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711453665.8A CN107937528B (zh) | 2017-12-28 | 2017-12-28 | 胶质瘤预后标志物hsa_circ_0125365及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711453665.8A CN107937528B (zh) | 2017-12-28 | 2017-12-28 | 胶质瘤预后标志物hsa_circ_0125365及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107937528A true CN107937528A (zh) | 2018-04-20 |
| CN107937528B CN107937528B (zh) | 2020-06-30 |
Family
ID=61940565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711453665.8A Expired - Fee Related CN107937528B (zh) | 2017-12-28 | 2017-12-28 | 胶质瘤预后标志物hsa_circ_0125365及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107937528B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109321657A (zh) * | 2018-10-30 | 2019-02-12 | 徐州医科大学 | 一种胶质瘤预后标志物及其应用 |
-
2017
- 2017-12-28 CN CN201711453665.8A patent/CN107937528B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| RYBAK-WOLF ET AL.: "Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed.", 《MOLECULAR CELL》 * |
| SALZMAN ET AL.: "Cell-Type Specific Features of Circular RNA Expression.", 《PLOS GENETICS》 * |
| YANG ET AL.: "Identification of circular RNA signature in bladder cancer.", 《JOURNAL OF CANCER》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109321657A (zh) * | 2018-10-30 | 2019-02-12 | 徐州医科大学 | 一种胶质瘤预后标志物及其应用 |
| CN109321657B (zh) * | 2018-10-30 | 2021-07-02 | 徐州医科大学 | 一种胶质瘤预后标志物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107937528B (zh) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104694623A (zh) | 一种用于肺癌诊断的血浆miRNA标志物及应用 | |
| CN108624693A (zh) | miR-577在制备肾病诊断标志物中的应用 | |
| CN107557472A (zh) | 胶质瘤诊断标志物circ9:135881633|135883078及应用 | |
| CN107937528A (zh) | 胶质瘤预后标志物hsa_circ_0125365及应用 | |
| CN107586844A (zh) | 胶质瘤预后标志物Circ9:135881633|135883078的应用 | |
| CN106755309A (zh) | 分子标记物在制备胰腺癌预后评估产品中的应用 | |
| CN107586848A (zh) | 胶质瘤预后标志物circ8:127890589|127890998及应用 | |
| JPWO2019117270A1 (ja) | 頭頸部がんの検出を補助する方法 | |
| CN107619869A (zh) | 胶质瘤诊断及预后标志物circ16:85633914|85634132及应用 | |
| CN107988370A (zh) | 一种circRNA基因在制备诊断慢性粒细胞性白血病试剂中的应用 | |
| CN107586849A (zh) | 脑组织来源的circ9:4117768|4118881的应用 | |
| CN107937530A (zh) | 胶质瘤预后标志物hsa_circ_0125361及应用 | |
| CN107604072A (zh) | 胶质瘤预后标志物circ15:98707562|98708107的应用 | |
| CN107937536A (zh) | 胶质瘤预后标志物circ19:47362476|47362693及应用 | |
| CN107586846A (zh) | 胶质瘤诊断标志物Circ3:129880309|129880559及应用 | |
| CN107604076A (zh) | 胶质瘤诊断标志物Circ6:4891713|4892379及应用 | |
| CN107604074A (zh) | 胶质瘤预后标志物circ15:101235082|101235577及应用 | |
| CN107937538A (zh) | 胶质瘤诊断标志物circ1:201817088|201817285及应用 | |
| CN104059987A (zh) | 骨肉瘤诊断试剂盒及cpe基因在其制备中的用途 | |
| CN107937529A (zh) | 胶质瘤诊断标志物hsa_circ_0135404及应用 | |
| CN107557441A (zh) | 胶质瘤诊断标志物Circ2:23823258|23823569及应用 | |
| CN107619868A (zh) | 胶质瘤预后标志物Circ3:129880309|129880559的应用 | |
| CN109371129A (zh) | hsa_circRNA_0000798作为肝癌早期诊断或预后评估生物标记物的应用 | |
| CN109295059A (zh) | 一种共价环状闭合的单链rna及其应用 | |
| CN107937540A (zh) | 胶质瘤诊断标志物circ17:47618350|47619164及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200630 |